BACKGROUND: Invasive disease-free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptorpositive (HR1), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph node-negative (LN-) tumors with a 21-gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes among patients with an RS of 11 to 25 who are treated with endocrine therapy alone are unknown. METHODS: In this retrospective single-institution study, the authors described the characteristics of patients with HR1, HER2-, LN-BC who underwent a 21-gene expression assay. In addition, among those individuals diagnosed between 2005 and 2011, we measured IDFS, recurrence-free survival, distant recurrence-free survival, and overall survival rates, focusing on patients with an RS of 11 to 25 by receipt of chemotherapy. The Kaplan-Meier method was used to estimate survival rates and multivariable Cox proportional hazards models were used to calculate hazard ratios and 95% confidence intervals (95% CIs). RESULTS: Among 1424 patients, the RS distribution was 0 to 10 in 297 patients (21%), 11 to 25 in 894 patients (63%), and >25 in 233 patients (16%); of these, 1.7%, 15%, and 73.4% of patients, respectively, received chemotherapy. With a median follow-up of 58 months, those patients with an RS of 11 to 25 had an IDFS rate at 5 years of 92.6% (95% CI, 89.6%-94.7%), which was comparable between those who received chemotherapy and those who did not. The hazard ratios of the effect of chemotherapy were 1.64 for IDFS (95% CI, 0.73-3.71), 1.46 for recurrence-free survival (95% CI, 0.41-5.23), 1.25 for distant recurrence-free survival (95% CI, 0.32-4.92), and 2.19 for overall survival (95% CI, 0.44-11.0). CONCLUSIONS: The results of the current study demonstrate similar outcomes with or without chemotherapy in patients with HR1, HER2-, LN-BC who have an RS of 11 to 25, but a benefit from chemotherapy in this group cannot be ruled out.
INTRODUCTION
Tumor gene expression profiling provides additional prognostic and predictive information to that obtained from traditional tumor histopathologic factors and biomarkers in patients with early-stage breast cancer (BC). 1 In the United States, the most widely used test is the 21-gene expression assay (Oncotype DX; Genomic Health Inc, Redwood City, Calif), which reports a recurrence score (RS) that estimates the 10-year risk of distant recurrence in patients with BC with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph nodenegative (LN-) disease. 2, 3 This assay has been validated in several independent data sets [4] [5] [6] [7] [8] and is recommended both by the American Society of Clinical Oncology and the National Comprehensive Cancer Network guidelines in the management of patients with HR1, HER2-, early-stage BC to assess the risk of disease recurrence and the potential benefit of adjuvant systemic therapy. 9, 10 Two prospective clinical trials reported excellent survival outcomes in patients with HR1, HER2-, early-stage BC with an RS of <11 who were treated with endocrine therapy only. The West German Study Group Phase III PlanB Trial demonstrated a 3-year disease-free survival rate of 98%. 11 The Trial Assigning Individualized Options for Treatment (TAILORx) reported an invasive disease-free survival (IDFS) rate of 93.8% at 5 years, and the risk of distant recurrence was <1% because the majority of events were second primary breast cancers or cancers from other sites, which are not expected to be affected by the receipt of chemotherapy. 12 After studies demonstrated the prognostic and predictive value of the 21-gene assay, 2, 7 the standard of care changed for the treatment of patients with HR1, HER2-, LN-, early-stage BC, and the use of tumor gene profiling became widespread in the United States. The original categorization of the 21-gene-based RS was 0 to 17 for low risk, 18 to 30 for intermediate risk, and >30 for high risk. 2, 7 By design, the TAILORx clinical trial investigators shifted the categorization of RS to the left of the continuum as a conservative measure to prevent the potential harm of not administering chemotherapy, and a "new" intermediate score was created; initial results support omitting chemotherapy in patients with an RS of 0 to 10. 3, 12 However, to the best of our knowledge, the results of the effects of chemotherapy in patients with an RS of 11 to 25 have not yet been reported.
To our knowledge, it is unknown whether chemotherapy provides any additional benefit in outcomes in patients with HR1, HER2-, LN-, early-stage BC with an RS of 11 to 25 who are treated with endocrine therapy. Therefore, we decided to describe the characteristics of patients who underwent a 21-gene expression assay in our institution and, in addition, we estimated IDFS, recurrence-free survival (RFS), distant recurrence-free survival (DRFS), and overall survival (OS) rates among those who had tumors with an RS of 11 to 25 and were diagnosed between 2005 and 2011 to allow for sufficient follow-up time.
MATERIALS AND METHODS
The current study was a single-institution retrospective descriptive analysis of a cohort of patients with a histologically confirmed diagnosis of HR1, HER2-, LN-, stage I to II BC who had received their initial treatment at The University of Texas MD Anderson Cancer Center (MDACC) in Houston and had undergone a 21-gene expression assay. Patients were identified and study data were collected from the Breast Cancer Management System database and from the patients' electronic medical charts. The current study was performed with approval from the MDACC Institutional Review Board (protocol PA15-0387) and a waiver of consent was obtained. The exclusion criteria consisted of those who had undergone any treatment for their BC before their initial visit to MDACC, those with LN-positive disease, and those with unknown tumor characteristics or missing treatment information; finally, we excluded patients who had enrolled and participated in the TAILORx clinical trial 12 at MDACC.
We assessed patients' demographic characteristics (age at diagnosis, race/ethnicity, sex, and menopausal status), tumor prognostic factors (size, histologic grade, histologic type, Ki-67 expression, and lymphovascular invasion [LVI]), and treatment received (type of surgery, radiotherapy, and endocrine therapy). The estrogen receptor, progesterone receptor, and HER2 status of the tumor were determined by immunohistochemical analysis or fluorescence in situ hybridization using institutional laboratory thresholds and following standard current guidelines. 13, 14 The tumor stage was determined using the sixth edition of the American Joint Committee on Cancer guidelines. 15 The last follow-up date for patients in this study was November 1, 2015.
Following the cutoff scores used in the TAILORx clinical trial, 12 we categorized the RS results in 3 groups: RS of 0 to 10, 11 to 25, and >25. Among those diagnosed between 2005 and 2011, we estimated IDFS, RFS, DRFS, and OS rates. We used the Standardized Definitions for Efficacy End Points 16 in adjuvant BC trial criteria to define such outcomes. We compared these outcomes of interest between patients who received chemotherapy with those who did not, focusing on those with an RS of 11 to 25. Patients were censored at the last date of follow-up. We determined the most recent vital status of each patient using data from the tumor registry at MDACC and via the review of the patient's medical record.
Statistical Analyses
Demographic characteristics were compared using the chi-square or Kruskal-Wallis test, as appropriate. We used the Kaplan-Meier product-limit method to estimate the survival function and the log-rank statistic to compare survival distributions by RS category. The multivariable Cox proportional hazards model was used to assess the effect of chemotherapy on IDFS, RFS, DRFS, and OS rates. 17 The following prespecified prognostic factors were considered for adjustment in the multivariable model: age at diagnosis, tumor size, grade, histologic subtype, Ki-67 expression, LVI, type of surgery, and endocrine therapy. If a prespecified confounding variable failed to produce stable estimate of effect because of a sparse distribution of events across its categories, we removed such a variable from the multivariable model. The proportional hazards assumption was assessed for the continuous variable using Martingale residuals.
In an effort to minimize selection bias, we also conducted a propensity score-matched analysis, obtaining the conditional probability of receiving chemotherapy given the known prognostic covariates. Propensity scores were obtained using a multivariable logistic regression model with a nearest neighborhood matching method to obtain 1:1 matched doublets. 18 Two-way interactions were introduced to improve the matching. We used absolute standardized differences to assess balance in the covariates between patients who received chemotherapy versus those who did not, in which a difference of <10% suggested a substantial reduction of bias. All statistical tests were performed using a 2-sided significance level of .05. Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) and STATA statistical software (version 12; StataCorp LP, College Station, Tex).
RESULTS
We identified 1424 patients who met the eligibility criteria ( Fig. 1 ), 99% of whom were female. Table 1 shows the characteristics of the study cohort grouped by RS category (RS of 0-10, 11-25, and >25). Age at diagnosis, menopausal status, and race/ethnicity were similarly distributed across RS categories. In the category of patients with an RS >25, there were more cases of invasive ductal carcinoma, fewer cases of invasive lobular carcinoma, and more tumors with Nottingham histological nuclear grade 3 and high Ki-67 expression compared with the other RS categories. However, the distribution of tumor stage was similar across the RS categories. It is interesting to note that in the RS category of 0 to 10, 11.5% of patients had tumors with nuclear grade 3, 26.6% had a Ki-67 expression level of > 14%, and 11.0% had LVI. The type of surgery and receipt of radiotherapy were relatively similar across the 3 RS categories. As expected, the rate at which patients received chemotherapy increased steadily with each RS category. Figure 2 depicts the distribution of patients and the percentage of patients who received chemotherapy by individual RS scores. It is interesting to note that the percentage of patients with an RS of 11 to 25 who received chemotherapy, which was approximately 15%, did not change substantially throughout the years. Table 2 shows the characteristics of 549 patients, all of whom were female, who were diagnosed between 2005 and 2011 with tumors with an RS of 11 to 25 categorized by receipt of chemotherapy. Patients who received chemotherapy were younger, had larger tumors, and had more stage II tumors compared with those who did not receive chemotherapy, with a tendency for these patients to also have higher Ki-67scores and more LVI. However, the distribution of the other demographic and tumor characteristics and treatments received were comparable. In these patients, after a median follow-up of 58 months (interquartile range, 46-73 months), there were 41 outcome events (overall rate of 7.5%): 10 distant recurrences, 3 local recurrences, 7 deaths, 11 second primary BCs, and 10 primary cancers at other sites. Figure 3 depicts the Kaplan-Meier curves for each outcome by receipt of chemotherapy for the RS categories of 11 to 25 and >25. There was no significant separation of the curves noted in any of the RS categories for any of the 4 outcomes. Figure 4 shows the results of the multivariable analysis of the effect of chemotherapy on each outcome in patients with an RS of 11 to 25 who were diagnosed between 2005 and 2011. In the multivariable model, we excluded the Ki-67 score due to a high frequency of missing values. All hazard ratios were >1.0, but none reached statistical significance. The estimated 5-year IDFS rates were 89% (95% confidence interval [95% CI], 80%-94%) and 93% (95% CI, 90%-95%), respectively, among those who received chemotherapy and those who did not. Similarly, the 5-year RFS rates were 95% (95% CI, 86%-98%) and 96% (95% CI, 94%-98%), respectively; the 5-year DRFS rates were 96% (95% CI, 87%-99%) and 96% (95% CI, 94%-98%), respectively; and the 5-year OS rates were 98% (95% CI, 91%-99%) and 98% (95% CI, 96%-99%), respectively, among those who received chemotherapy and those who did not. Among patients who had tumors with an RS >25, all hazard ratios were <1.0, suggesting a benefit from chemotherapy; however, statistical significance was not reached. Among patients with an RS of 11 to 25 who were diagnosed between 2005 and 2011, 92 received chemotherapy. The logistic regression-based propensity score model selected a matched cohort of 178 patients, in which 89 patients received chemotherapy and 89 did not. The balance statistics of the distribution of the confounding variables in patients who received chemotherapy and those who did not demonstrated that patients were well matched with regard to their prognostic factors (see Supporting Information Table 1 ). Findings in the survival differences (see Supporting Information Fig. 1 ) in this matched cohort were consistent with those in our primary analysis.
DISCUSSION
In this large, single-institution, unselected cohort of patients with early-stage, HR1, HER2-, LN-BC, among those patients with tumors with an RS of 11 to 25, we found similar outcomes among those who received chemotherapy compared with those who did not. These results were limited by the low number of events and by the relatively short median follow-up. Among those patients who did not receive chemotherapy, the estimated rates of freedom from outcomes at 5 years ranged from an IDFS rate of 93% to an OS rate of 98%, which are very good and comparable to those of patients who did receive chemotherapy. It is interesting to note that the 5-year IDFS rate reported herein was very close to the rate of 93.8% reported by the TAILORx trial for the subgroup of patients with an RS of 0 to 11, and also was close to the 92% predefined lower boundary of the 95% CI of the rate of 5-year survival without distant metastasis reported in the Microarray in Lymph node-Negative and 1 to 3 Positive Lymph node Disease May Avoid Chemotherapy (MINDACT) study.
12,19
The benefits of chemotherapy always must be balanced against its short-term and long-term side effects; therefore, estimates of risks are essential for making clinical decisions. BC represents a variety of different diseases, and we currently have prognostic and predictive biomarkers of treatment effectiveness. 20 The standard of care for the treatment of patients with HR1, HER2-, LN-, early-stage BC using a tumor gene profiling assay has become widespread in the United States. After the original classification of the 21-gene-based RS was suggested to be 0 to 17 for patients at low risk, 18 to 30 for patients at intermediate risk, and >30 for patients at high risk, 2,7 the benefit of chemotherapy for patients with tumors classified as intermediate risk has since remained unclear. Original Article A report from the Clalit Health Services of 1594 patients with early-stage BC with HR1, HER2-, and LN-or LN-microscopic disease demonstrated that among those with an intermediate RS of 18 to 30, there were no differences in distant recurrence noted between those who underwent chemotherapy and those who did not. 21, 22 The report from the MINDACT investigators demonstrated that among 1550 female patients with early-stage BC (26% of whom had LN-positive disease) who were classified as having a high clinical risk for disease recurrence using a modified version of Adjuvant! Online 23 and low genomic risk using a 70-gene signature, those who received chemotherapy experienced a nonsignificant 1.5% improvement in the 5-year rate of survival without distant metastasis. 19 It is interesting to note that if we were to apply the same criteria used by the MINDACT study, 72.5% of the patients in the current study with an RS of 11 to 25 (398 of 549 patients) would have been classified as being of low clinical risk and would have not benefited from chemotherapy. As a planned conservative measure, the TAILORx clinical trial investigators decided to shift the categorization of RS to the left of the continuum, and a "new" intermediate score then was created. 3, 12 Initial results demonstrated a very low event rate at 5 years among patients with tumors with a "very low" RS of 0 to 10. Comparable results were observed in the West German Study Group Phase III PlanB Trial. 11 These results clearly justify omitting chemotherapy in patients with an RS of 0 to 10. The benefits of chemotherapy in patients with an RS of 11 to 25 will remain unclear until we learn the outcome results of the 6897 patients in the TAILORx trial who were randomly assigned to chemotherapy versus no chemotherapy. Although the results of the current study demonstrated similar outcomes between those patients who received chemotherapy compared with those who did not in the group of patients with an RS of 11 to 25, we clearly do not promote a change in current clinical practice because the current study did not have the statistical power to demonstrate a difference. It was interesting to observe that known prognostic tumor variables do not appear to correlate entirely with the RS. As seen by others, 11, 12 there is a small but considerable percentage of patients who have tumors with an RS of <11 but have grade 3 disease, high Ki-67 expression levels, and high LVI, which traditionally are considered to be tumor highrisk factors. Therefore, determining the RS of tumors with these characteristics is justifiable.
Recent US population-based studies have reported on trends regarding the use of the 21-gene RS assay associated with variables of interest. Using the National Cancer Data Base, investigators identified 143,032 patients with early-stage BC, 54% of whom had the RS assay performed, which significantly influenced clinicians' recommendation of chemotherapy, with significant differences noted in its use by race, type of insurance, and facility. 24 A Surveillance, Epidemiology, and End Results populationbased study of 38,568 patients with BC demonstrated unadjusted 5-year BC-specific mortality rates of 0.4%, 1.4%, and 4.4%, respectively, in patients with RS of <18, 18 to 30, and >30; however, due to underreporting of chemotherapy in Surveillance, Epidemiology, and End Results and a possible selection bias, the investigators did not report outcomes by treatment choice. 25 Using the Pennsylvania Cancer Registry, investigators identified a retrospective cohort of 7287 patients with early-stage BC among whom use of the RS assay was associated with a decrease in the use of chemotherapy and lower costs in women aged <55 years and a modest increase in chemotherapy use and costs among patients aged 75 years. 26 The Carolina Breast Cancer Study of 1468 women reported no racial disparities with regard to RS testing for patients with LN-disease, although black women had tumors with worse known prognostic markers, such as high tumor grade and tumor size. 27 The current study has several limitations, of which the main one is its relatively short follow-up, which may explain the low number of events. In addition, a relatively low number of patients with an RS of 11 to 25 received chemotherapy. However, the Kaplan-Meier curves in the RS category of 11 to 25 did not demonstrate any separation, whereas there was a minuscule separation in the RS category of >25. In addition, the estimated 5-year rates of freedom from all outcomes were 93%. Therefore, we decided to run an exploratory analysis using the original RS cutoff points of <18, 18 to 30, and >30, which demonstrated a separation of the curves (P 5 .12) among the subset of patients with an RS >30; the results of the Figure 4 . Multivariable analysis of patients who received chemotherapy versus those who did not by recurrence score (RS) category. 95% CI, 95% confidence interval; DRFS, distant recurrence-free survival; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall survival; RFS, recurrence-free survival. multivariable analysis suggest that chemotherapy was beneficial in patients with an RS >30 (see Supporting Information Table 2 ). The other limitations of the current study are those that are inherent to retrospective studies, such as unbalanced characteristics among comparison groups and selection bias, which is the reason we performed a propensity score-matched analysis.
In this single-institution, retrospective descriptive study of a cohort of patients with early-stage, HR1, HER2-, LN-BC, after a median follow-up of 58 months, high RFS and IDFS rates were found among those who had an RS of 11 to 25, and there were similar outcomes noted among patients who received chemotherapy compared with those who did not. A benefit from chemotherapy in this group cannot be ruled out because a longer follow-up is required to observe future events.
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